viral
respiratori
infect
caus
signific
morbid
mortal
infant
young
children
well
atrisk
adult
elderli
although
mani
viral
pathogen
capabl
caus
respiratori
diseas
vaccin
develop
focu
limit
number
pathogen
commonli
caus
seriou
lower
respiratori
ill
lri
wherea
influenza
viru
vaccin
avail
time
see
review
clark
lynch
issu
vaccin
medic
import
virus
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
metapneumoviru
mpv
avail
review
aim
provid
brief
updat
investig
vaccin
rsv
piv
mpv
evalu
clinic
trial
current
clinic
develop
transmiss
rsv
mpv
piv
occur
via
airborn
particl
droplet
direct
contact
upper
respiratori
tract
urt
epitheli
cell
thought
usual
port
entri
viru
airborn
particl
might
also
transmit
directli
lower
respiratori
tract
lrt
rsv
mpv
piv
replic
limit
respiratori
tract
throughout
cours
diseas
viremia
system
spread
occur
immunocompet
host
viru
replic
take
place
polar
epitheli
cell
progeni
viru
bud
apic
surfac
cell
lumen
respiratori
tract
primari
rsv
infect
urt
estim
progress
clinic
lri
infect
children
risk
factor
associ
sever
lri
includ
young
age
underli
lung
diseas
eg
result
prematur
birth
genet
determin
environment
factor
cigarett
smoke
exposur
malnutrit
cytopath
effect
cpe
viral
infect
primari
respiratori
epitheli
cell
differ
greatli
individu
respiratori
virus
although
primari
influenza
viru
pneumonia
character
extens
cpe
destruct
respiratori
epithelium
rsv
piv
caus
limit
cpe
primari
human
airway
epitheli
cell
direct
viral
effect
function
epitheli
cell
eg
reduc
ciliari
beat
increas
mucu
product
report
consist
observ
untreat
fatal
rsv
diseas
cellular
infiltr
domin
histopatholog
suggest
host
immun
respons
contribut
significantli
clinic
diseas
viru
titer
respiratori
tract
seem
correl
well
magnitud
inflammatori
respons
diseas
sever
experiment
infect
healthi
adult
rsv
titer
also
correl
ill
sever
infant
natur
acquir
rsv
infect
reactiv
airway
diseas
rad
describ
longterm
consequ
rsv
lrti
first
year
life
cohort
studi
suggest
sever
lrti
longer
consequ
persist
contribut
innat
immun
respons
resolut
suscept
viral
respiratori
ill
better
appreci
year
ago
due
part
increas
number
genet
suscept
studi
suggest
role
surfact
protein
cytokin
pattern
recognit
receptor
protect
sever
rsv
diseas
also
due
much
broader
interest
better
understand
innat
immun
gener
cytotox
lymphocyt
ctl
respons
wide
recogn
play
import
role
resolv
primari
infect
evid
contribut
protect
diseas
upon
reinfect
howev
virusspecif
cell
respons
short
live
ctl
may
even
contribut
rsv
pathogenesi
thelper
type
respons
gener
view
benefici
wherea
respons
implic
advers
outcom
rsv
diseas
recent
studi
observ
inadequ
rather
exaggeratedt
cell
respons
fatal
rsv
diseas
lung
tissu
infant
fatal
rsv
bronchiol
posit
lymphocyt
immunoglobulin
igm
igg
igaposit
plasma
cell
promin
posit
cell
high
titer
viru
neutral
serum
antibodi
direct
two
larg
surfac
glycoprotein
wide
accept
correl
longterm
protect
diseas
mucos
antibodi
induc
primari
infect
also
effect
restrict
replic
challeng
viru
studi
suggest
mucos
neutral
antibodi
even
better
correl
protect
serum
antibodi
mucos
antibodi
titer
wane
period
month
follow
primari
infect
reinfect
need
titer
persist
high
titer
serum
neutral
antibodi
igg
may
gain
access
lumin
surfac
lrt
transud
restrict
viru
replic
local
howev
transud
effici
mechan
urt
mucos
iga
antibodi
play
domin
role
correl
longterm
protect
virusspecif
iga
igm
igg
nasopharyng
secret
associ
better
oxygen
satur
infant
rsv
influenza
lri
agreement
observ
palivizumab
parenter
administ
monoclon
igg
antibodi
prepar
use
rsv
prophylaxi
highrisk
infant
decreas
titer
infecti
rsv
tracheal
secret
nasal
secret
intub
infant
within
day
palivizumab
treatment
initi
howev
higheraffin
rsv
antibodi
motavizumab
shown
reduc
rsv
infect
rsv
rna
level
urt
secret
indic
transfer
serum
igg
across
mucos
urt
membran
occur
except
influenza
viru
vaccin
temporarili
adenoviru
type
vaccin
use
militari
licens
vaccin
prevent
viral
acut
respiratori
diseas
avail
notwithstand
obviou
medic
need
vaccin
spite
mani
year
activ
vaccin
research
suggest
formid
obstacl
overcom
tabl
first
challeng
primari
infect
rsv
piv
mpv
provid
durabl
protect
reinfect
although
diseas
upon
reinfect
usual
amelior
restrict
urt
adult
repeatedli
experiment
challeng
rsv
least
could
reinfect
within
month
first
challeng
similarli
mpvexperienc
healthi
adult
reinfect
homolog
challeng
viru
viru
shed
uri
observ
volunt
infant
children
diseas
sever
decreas
increas
number
reinfect
therefor
surpris
lri
frequent
seen
primari
infect
follow
secondari
tertiari
infect
realist
goal
immun
reduct
sever
diseas
rather
induct
steril
immun
similar
achiev
rotaviru
vaccin
second
although
high
titer
neutral
serum
igg
abl
prevent
lri
via
transud
lumin
surfac
lrt
mucos
immun
crucial
protect
urt
prevent
spread
lrt
howev
induct
persist
protect
mucos
immun
requir
one
infect
one
dose
vaccin
therefor
need
induc
durabl
immun
third
vaccin
need
protect
young
infant
elderli
differ
vaccin
separ
approach
like
need
protect
two
highrisk
group
clinic
evalu
candid
vaccin
start
healthi
young
adult
progress
younger
andor
older
age
group
thu
increas
time
need
clinic
vaccin
develop
live
attenu
vaccin
appropri
attenu
seroneg
infant
certainli
overattenu
elderli
fourth
young
infant
less
like
develop
high
titer
neutral
antibodi
limit
b
cell
repertoir
ineffici
antigen
present
limit
cell
help
might
contribut
observ
addit
first
month
life
matern
acquir
igg
exert
immunosuppress
effect
particularli
humor
immun
respons
use
live
attenu
viru
vaccin
infect
urt
may
circumv
neutral
effect
matern
acquir
serum
antibodi
necessarili
guarante
induct
robust
immun
respons
clinic
trial
attenu
rsv
candid
vaccin
emphas
challeng
determin
valid
correl
protect
infant
younger
month
age
rsv
vaccin
trial
infant
children
instanc
viru
neutral
serum
igg
could
detect
infant
less
month
age
wherea
children
month
age
develop
greater
fourfold
increas
neutral
antibodi
titer
trial
increas
virusspecif
serum
iga
seem
best
still
imperfect
correl
protect
detect
vaccine
despit
inabl
defin
sensit
specif
vitro
correl
protect
young
infant
protect
replic
second
dose
vaccin
viru
indic
young
infant
develop
protect
immun
respons
first
attempt
develop
rsv
vaccin
employ
formalininactiv
fi
whole
viru
firsv
adjuv
alum
vaccin
fail
induc
protect
immun
respons
led
enhanc
diseas
upon
natur
infect
wildtyp
wt
rsv
result
vaccine
need
hospit
follow
wt
rsv
infect
two
children
die
subsequ
great
apprehens
surround
clinic
develop
whole
viru
nonrepl
rsv
vaccin
use
rsv
seroneg
infant
children
enhanc
diseas
never
observ
live
attenu
vaccin
seen
seroposit
subject
neither
inactiv
subunit
rsv
vaccin
sever
purifi
f
protein
vaccin
wyeth
evalu
clinic
trial
adult
children
author
knowledg
program
longer
activ
purifi
f
protein
aluminum
phosphat
test
seroposit
children
year
age
cystic
fibrosi
although
vaccin
found
safe
immunogen
seem
confer
protect
effect
similarli
trial
healthi
pregnant
women
offspr
indic
safe
signific
increas
rsv
neutral
igg
titer
follow
vaccin
third
trimest
protect
effect
offspr
could
expect
candid
vaccin
pierr
fabr
develop
fuse
conserv
central
domain
rsv
g
protein
albuminbind
region
streptococc
protein
g
vaccin
appear
safe
immunogen
phase
phase
studi
howev
unexpect
side
effect
phase
trial
purpuratyp
iii
hypersensit
small
number
vaccin
recipi
halt
develop
preclin
clinic
develop
live
attenu
rsv
piv
vaccin
use
infant
long
histori
help
concept
develop
guid
decis
make
first
sever
ill
follow
wildtyp
viru
infect
correl
level
viru
replic
ie
peak
viru
titer
respiratori
tract
convers
restrict
viru
replic
correl
attenu
certain
threshold
clinic
diseas
absent
infrequ
second
anim
model
permiss
viru
replic
seroneg
human
infant
clinic
studi
target
popul
key
select
appropri
attenu
vaccin
viru
develop
nonetheless
seroneg
rodent
nonhuman
primat
well
primari
human
airway
epitheli
cell
help
select
vaccin
viru
good
chanc
appropri
attenu
infant
third
attenu
phenotyp
live
attenu
vaccin
enhanc
success
import
individu
point
mutat
set
attenu
point
mutat
relat
anim
human
virus
conserv
sequenc
homolog
protein
inform
select
attenu
mutat
fourth
point
mutat
stabil
increas
genet
phenotyp
stabil
vaccin
delet
amino
acid
residu
site
attenu
point
mutat
codon
stabil
amino
acid
assign
stabil
mani
instanc
identifi
codon
would
requir
two
three
nucleotid
chang
revert
amino
acid
lead
loss
attenu
phenotyp
stabil
codon
increas
genet
phenotyp
stabil
vaccin
virus
also
manifest
increas
level
temperatur
sensit
attenu
compar
origin
mutant
help
attenu
slightli
underattenu
candid
vaccin
sinc
vaccin
viru
replic
correl
immunogen
reactogen
attempt
made
either
increas
antigen
express
infect
host
cell
enhanc
immun
respons
given
level
replic
strategi
review
elsewher
least
mention
first
paramyxoviru
gene
closer
end
viral
genom
express
effici
express
import
antigen
enhanc
shift
respect
gene
promoterproxim
posit
second
gene
regul
viral
rna
synthesi
rsv
gene
downregul
mrna
synthesi
delet
third
codon
usag
import
antigen
optim
enhanc
express
fourth
cytokin
may
improv
immunogen
coexpress
addit
gene
within
recombin
viral
genom
granulocytemacrophag
colonystimul
factor
gmcsf
instanc
coexpress
enhanc
antigen
present
dendrit
cell
matur
fifth
mutat
inactiv
viral
interferon
antagonist
lead
increas
type
interferon
product
host
therebi
increas
vaccin
immunogen
viruslik
particl
vlp
form
selfassembl
viral
structur
protein
contain
viral
genom
thu
abl
replic
one
advantag
vlp
viral
protein
good
chanc
present
infecti
viru
ie
viral
protein
arrang
nativ
conform
oligomer
state
within
viruss
particl
fusion
protein
paramyxovirus
instanc
arrang
homotrim
viral
envelop
trimer
import
function
antigen
vlp
thought
induc
strong
b
cell
respons
highli
repetit
surfac
particl
abl
crosslink
specif
b
cell
receptor
vlpbase
vaccin
fairli
recent
develop
far
two
pathogen
target
approv
vlpbase
vaccin
hepat
b
viru
human
papillomaviru
howev
mani
vlpbase
vaccin
clinic
develop
one
vlpbase
rsv
vaccin
enter
clinic
trial
briefli
discuss
articl
sever
replic
defect
vector
employ
vaccin
develop
two
system
mention
alphaviru
vector
adenoviru
vector
current
use
rsv
vaccin
develop
alphaviru
vector
use
express
sever
antigen
includ
influenza
viru
cytomegaloviru
cmv
alphavirus
eg
venezuelan
equin
enceph
viru
semliki
forest
viru
singlestrand
positivesens
rna
genom
encod
viral
nonstructur
protein
includ
viral
polymeras
portion
genom
structur
protein
portion
wherea
nonstructur
protein
translat
directli
viral
genom
rna
structur
protein
translat
subgenom
rna
transcrib
promot
present
fulllength
neg
strand
rna
replic
intermedi
structur
protein
code
region
delet
genom
gene
gene
interest
insert
place
selfrepl
rna
replicon
vector
form
alphaviru
particl
go
singl
replic
cycl
lead
cytoplasmat
express
foreign
gene
alphaviru
replicon
vaccin
noteworthi
abil
induc
mucos
immun
respons
follow
system
administr
shown
induc
protect
immun
rsv
respiratori
tract
cotton
rat
alphaviru
vectorbas
vaccin
influenza
cmv
alphavax
durham
nc
evalu
clinic
clinic
data
rsv
vaccin
base
technolog
avail
yet
recombin
replic
defect
adenoviru
rad
vector
evalu
extens
candid
hiv
vaccin
ad
serotyp
fact
doublestrand
dna
virus
accommod
larg
foreign
gene
insert
make
valuabl
vaccin
rad
serotyp
stand
best
character
ad
serotyp
also
immunogen
mani
other
good
induc
cytotox
cell
immun
initi
robust
antibodi
respons
although
ad
vector
mostli
use
system
administ
vaccin
recent
result
nonhuman
primat
studi
indic
also
deliv
aerosol
induc
mucos
immun
well
cell
respons
two
concern
frequent
mention
consid
vector
vaccin
platform
first
adult
seroposit
preexist
immun
known
reduc
immunogen
system
administ
vector
antigen
second
concern
result
recent
phase
hiv
vaccin
trial
step
trial
vector
express
hiv
antigen
fail
protect
vaccine
exploratori
analysi
seroposit
men
found
increas
risk
hiv
acquisit
mechan
underli
observ
still
understood
rad
serotyp
low
seropreval
human
explor
altern
characterist
radbas
rsv
vaccin
vector
recent
review
elsewher
platform
potenti
adult
pediatr
vaccin
radbas
rsv
vaccin
evalu
preclin
part
collabor
nation
institut
allergi
infecti
diseas
niaid
vaccin
research
center
genvec
inc
clinic
develop
plan
candid
subunit
vaccin
evalu
recent
clinic
trial
subunit
vaccin
contain
rsva
f
g
protein
sanofi
pasteur
swiftwat
pa
vaccin
evalu
doserang
studi
adult
year
age
older
tabl
vaccin
reactogen
similar
seen
season
influenza
viru
vaccin
inject
site
tender
common
local
advers
event
surprisingli
nonadjuv
adjuv
highdos
vaccin
induc
rise
neutral
antibodi
titer
rsv
vaccine
similar
result
ie
nonadjuv
subunit
vaccin
immunogen
aluminumphosph
adjuv
vaccin
obtain
trial
vaccin
older
adult
cardiopulmonari
diseas
tabl
studi
subunit
vaccin
appear
safe
immunogen
interfer
humor
respons
influenza
vaccin
suggest
vaccin
could
potenti
offer
benefit
older
adult
rsv
antibodi
titer
return
baselin
within
year
impli
annual
immun
would
necessari
sever
live
attenu
rsv
vaccin
develop
serial
passag
rsv
increasingli
lower
temperatur
cold
passag
cp
chemic
mutagenesi
temperaturesensit
ts
nont
attenu
mutat
identifi
sever
biolog
deriv
candid
vaccin
went
clinic
trial
prove
difficult
find
appropri
balanc
immunogen
attenu
particularli
infant
rsv
vaccin
instanc
replic
accept
titer
infant
replic
second
dose
vaccin
given
week
first
dose
highli
restrict
indic
protect
immun
induc
howev
infant
shed
pfuml
dose
experienc
nasal
congest
fussi
tri
sleep
mild
difficulti
feed
last
approxim
day
although
none
infant
develop
profus
rhinorrhea
otiti
media
fever
lri
vaccin
consid
reactogen
continu
clinic
develop
avail
revers
genet
system
rsv
sinc
enabl
direct
ration
rsv
vaccin
develop
approach
system
permit
gener
infecti
viru
cdna
copi
negativesens
singlestrand
viru
genom
thu
sitedirect
mutagenesi
could
use
introduc
specif
mutat
rsv
genom
evalu
contribut
mutat
attenu
att
phenotyp
use
methodolog
genet
basi
attenu
phenotyp
cprsv
cptsrsv
mutant
determin
addit
revers
genet
allow
target
delet
interferon
antagonist
gene
andor
well
delet
small
hydrophob
sh
gene
regul
transcript
replic
delet
mutant
turn
insuffici
attenu
use
infant
attenu
delet
mutant
respect
consid
promis
rsv
candid
vaccin
prepar
clinic
trial
delet
mutant
especi
attract
delet
protein
increas
viral
mrna
transcript
simultan
decreas
genom
replic
thu
vaccin
viru
expect
express
antigen
especi
f
g
live
attenu
rsv
vaccin
apart
aforement
delet
mutant
yet
enter
clinic
trial
mutant
design
seem
bear
great
potenti
mutant
rsv
contain
mutat
identifi
biolog
deriv
two
addit
attenu
mutat
introduc
ie
sh
gene
delet
one
amino
acid
substitut
gener
larg
polymeras
protein
lthe
mutat
evalu
phase
trial
infant
target
popul
pediatr
rsv
vaccin
found
well
toler
immunogen
slightli
underattenu
mutant
neither
system
mucos
antibodi
respons
consist
observ
infant
replic
second
dose
vaccin
given
week
first
dose
highli
restrict
indic
protect
immun
induc
medimmun
llc
gaithersburg
md
current
evalu
vaccin
refer
children
month
age
trial
children
random
receiv
three
dose
vaccin
month
although
enrol
complet
data
analysi
trial
pend
tabl
live
respiratori
vaccin
attenu
combin
point
mutat
import
assess
vaccin
genet
phenotyp
stabil
transmiss
less
attenu
revert
vaccin
viru
concern
achiev
phenotyp
stabil
vaccin
virus
gener
encod
multipl
attenu
mutat
loss
one
two
mutat
result
viru
replic
well
wt
viru
altern
gene
delet
mutant
use
given
easili
revert
wt
sequenc
delet
mutant
mention
earlier
exampl
vaccin
evalu
clinic
vaccin
elderli
atrisk
adult
howev
even
dose
high
pfu
vaccin
viru
shed
adult
vaccine
develop
signific
antibodi
respons
although
viru
overattenu
adult
seroposit
children
shed
high
titer
vaccin
viru
shed
tempor
associ
uri
seroneg
infant
indic
vaccin
underattenu
cohort
singl
live
attenu
vaccin
two
target
popul
feasibl
two
gene
delet
mutant
encod
addit
attenu
point
mutat
also
evalu
rsvseroneg
children
delet
gene
decreas
infect
vaccin
virus
seroneg
children
month
age
respect
restrict
replic
level
pfuml
longer
associ
upper
respiratori
ill
howev
two
vaccin
candid
appear
overattenu
insuffici
immunogen
bival
vaccin
discuss
end
section
gener
envelop
vlp
compos
rsv
protein
report
fairli
ineffici
howev
envelop
vlp
compos
newcastl
diseas
viru
ndv
nucleocapsid
matrix
protein
well
chimer
rsvndv
glycoprotein
gener
effici
chimer
glycoprotein
consist
ectodomain
rsv
f
g
protein
transmembran
cytoplasm
domain
ndv
f
hn
respect
cytoplasm
domain
ndv
f
hn
shown
interact
ndv
protein
interact
thought
support
vlp
format
via
bud
cell
surfac
vlp
base
technolog
shown
induc
high
titer
rsvneutral
serum
antibodi
follow
intramuscular
vaccin
mice
igg
subclass
ratio
suggest
strong
respons
initi
mice
protect
wt
rsv
challeng
week
postimmun
vlp
express
rsv
f
enter
phase
dose
escal
studi
healthi
adult
detail
vlp
design
yet
avail
tabl
second
rsv
caus
viral
bronchiol
pneumonia
infant
children
although
studi
mpv
compet
rsv
live
attenu
vaccin
candid
develop
serial
tissu
cultur
passag
wt
viru
suboptim
temperatur
one
candid
vaccin
coldpassag
cp
time
acquir
set
mutat
confer
cold
adapt
ca
temperatur
sensit
ts
attenu
att
phenotyp
evalu
phase
trial
infant
young
month
age
found
appropri
attenu
immunogen
target
popul
infant
receiv
two
dose
vaccin
either
month
apart
first
dose
vaccin
infect
infant
vaccin
viru
shed
low
titer
day
mean
replic
second
dose
vaccin
restrict
indic
immun
young
infant
result
induct
protect
immun
nonetheless
two
three
dose
vaccin
like
need
induc
durabl
immun
serum
igg
antibodi
respons
observ
minor
young
infant
possibl
due
presenc
matern
igg
serum
iga
antibodi
direct
hn
glycoprotein
seem
sensit
correl
immun
phase
trial
children
month
age
includ
infant
children
seroneg
vaccin
well
toler
differ
observ
frequenc
uri
cough
fever
otiti
media
vaccin
placebo
recipi
eightyfour
percent
seroneg
vaccin
recipi
develop
fourfold
greater
increas
antibodi
titer
indic
satisfactori
infect
immunogen
addit
intranas
vaccin
singl
bival
dose
pfu
per
viru
evalu
seroneg
children
although
slight
reduct
infect
observ
combin
vaccin
vs
monoval
vaccin
combin
vaccin
immunogen
antibodi
respons
compar
monoval
group
follow
forego
trial
vaccin
viru
rederiv
cdna
refer
recombin
r
reduc
risk
potenti
biolog
contamin
vaccin
seed
viru
addit
technolog
also
permit
rederiv
vaccin
seed
viru
cdna
time
clinic
develop
conduct
cooper
research
develop
agreement
niaid
medimmun
llc
current
two
phase
trial
sponsor
niaid
first
protocol
enrol
total
children
month
age
two
cohort
random
receiv
two
dose
tcid
placebo
week
apart
tabl
first
cohort
unscreen
infant
month
age
frequent
nasal
wash
perform
quantit
virolog
unscreen
cohort
seroneg
vaccine
vaccin
viru
detect
nasal
wash
approxim
week
mean
peak
titer
tcid
ml
wherea
two
five
seroposit
vaccine
vaccin
viru
detect
singl
day
mean
peak
titer
tcid
ml
one
vaccine
shed
vaccin
follow
second
dose
suggest
protect
immun
respons
restrict
replic
vaccin
viru
addit
seroneg
children
month
age
enrol
expand
safeti
immunogen
data
find
first
cohort
regard
safeti
infect
immunogen
confirm
although
found
safe
well
toler
immunogen
indistinguish
regard
biolog
deriv
dose
interv
month
clearli
insuffici
permit
reinfect
boost
immun
respons
two
addit
studi
seroneg
children
month
age
initi
evalu
two
dose
vaccin
given
month
apart
tabl
medimmun
initi
trial
evalu
three
dose
given
month
apart
regimen
immunogen
well
toler
tabl
second
approach
develop
vaccin
use
host
rang
mutant
bovin
viru
cattl
antigen
relat
human
restrict
replic
nonhuman
primat
test
phase
studi
infant
children
prove
infecti
well
toler
immunogen
howev
antigen
differ
glycoprotein
antibodi
titer
lower
fourdos
regimen
evalu
phase
trial
infant
month
old
receiv
tissu
cultur
infect
dose
tcid
tcid
placebo
month
age
either
dose
well
toler
advers
event
occur
similar
frequenc
vaccin
placebo
recipi
except
fever
second
dose
common
vaccin
recipi
observ
phase
studi
alreadi
mention
seroconvers
rate
satisfactori
modest
chimer
recombin
bovinehuman
viru
bear
hn
f
gene
encod
glycoprotein
target
neutral
antibodi
place
gene
found
immunogen
rhesu
monkey
unmodifi
retain
attenu
phenotyp
candid
vaccin
recent
evalu
healthi
adult
well
seroposit
seroneg
children
tabl
adult
seroposit
children
infect
minor
subject
poorli
immunogen
expect
seroneg
children
vaccin
viru
highli
infecti
dose
tcid
vaccin
recipi
develop
fourfold
greater
rise
hai
hemagglutinationinhibit
antibodi
titer
mean
peak
titer
vaccin
viru
shed
log
tcid
similar
mean
peak
titer
observ
seroneg
children
although
uri
fever
fairli
frequent
followup
rate
similar
vaccine
placebo
recipi
unpublish
result
chimer
virus
note
earlier
modifi
express
either
rsv
f
protein
alon
g
f
protein
addit
gene
insert
genom
construct
function
bival
vaccin
viru
express
major
protect
antigen
rsv
construct
develop
medimmun
niaid
respect
medimmun
construct
express
rsv
f
protein
refer
well
toler
seroposit
children
separ
studi
children
month
age
seroneg
rsv
subject
receiv
tcid
seroconvert
rsv
respect
tabl
incid
advers
event
solicit
event
similar
placebo
group
relat
niaid
construct
enter
clinic
trial
yet
mpv
similar
rsv
genom
organ
also
epidemiolog
spectrum
diseas
natur
vaccin
develop
mpv
follow
exampl
rsv
vaccin
develop
recombin
system
gener
viru
cdna
set
within
year
initi
isol
mpv
gene
delet
experi
quickli
defin
nonessenti
gene
delet
sh
gene
littl
attenu
viru
african
green
monkey
agm
virus
lack
attach
glycoprotein
g
protein
restrict
replic
second
approach
develop
live
attenu
mpv
candid
vaccin
follow
exampl
ie
chimer
viru
deriv
cdna
gene
nonhuman
viru
substitut
homolog
gene
human
mpv
avian
mpv
ampv
caus
agent
respiratori
diseas
poultri
use
ampv
restrict
replic
agm
report
human
diseas
caus
ampv
although
mani
employe
poultri
industri
expos
viru
n
p
gene
ampv
substitut
individu
respect
gene
hmpv
recombin
chimer
viru
chimer
viru
express
ampv
p
protein
hmpvpa
restrict
lrt
agm
chimer
viru
express
ampv
n
protein
significantli
attenu
hmpvpa
therefor
appear
attract
live
attenu
mpv
vaccin
candid
prior
initi
clinic
trial
hmpvpa
wtlike
cdnaderiv
hmpv
evalu
clinic
trial
healthi
adult
establish
benchmark
regard
infect
replic
abil
pfu
wtlike
hmpv
given
adult
inpati
isol
facil
subject
observ
minimum
day
prior
discharg
wtlike
viru
infect
approxim
half
subject
adult
shed
detect
viru
develop
mild
uri
subsequ
hmpvpa
administ
adult
found
expect
poorli
infecti
immunogen
adult
studi
seroposit
children
initi
tabl
like
wait
studi
seroneg
children
learn
whether
viru
appropri
attenu
immunogen
target
popul
live
attenu
candid
vaccin
gener
import
one
known
attenu
point
mutat
heterolog
paramyxovirus
mutat
found
conserv
region
murin
sendai
viru
introduc
pc
f
hn
andor
l
gene
mutant
evalu
hamster
nonhuman
primat
one
vaccin
candid
contain
two
substitut
pc
gene
one
substitut
l
gene
found
highli
attenu
agm
yet
confer
protect
wt
challeng
induc
robust
antibodi
respons
codon
mutat
c
protein
vaccin
viru
particularli
interest
abrog
abil
evad
host
immun
respons
unlik
wt
mutant
stimul
interferon
express
permit
interferon
signal
thu
induc
earlier
like
potent
innat
immun
respons
wt
part
defect
mutant
inhibit
doublestrand
rna
accumul
well
wt
result
activ
cytoplasm
viral
sensor
pkr
stabil
identifi
mutat
mutat
c
protein
chang
delet
codon
origin
mutat
l
protein
modifi
gener
mutant
viru
possess
similar
ts
phenotyp
would
requir
three
nucleotid
substitut
revert
viru
wt
growth
phenotyp
vivo
stabil
vaccin
viru
current
phase
trial
seroneg
children
tabl
although
studi
complet
enrol
yet
preliminari
data
indic
vaccin
viru
replic
highli
restrict
seroneg
children
develop
live
attenu
vaccin
five
missens
mutat
found
larg
polymeras
l
protein
attenu
rsv
mutant
import
homolog
posit
l
protein
three
mutat
confer
temperatur
sensit
vitro
restrict
replic
vivo
attenu
mutat
l
either
stabil
codon
delet
codon
increas
genet
phenotyp
stabil
addit
spontan
c
nucleotid
substitut
within
extragen
leader
region
genom
also
contribut
attenu
includ
candid
vaccin
investig
vaccin
refer
includ
leader
mutat
well
amino
acid
substitut
delet
codon
l
protein
viru
highli
attenu
agm
provid
protect
wt
challeng
replic
also
restrict
fulli
differenti
primari
human
airway
epithelium
suggest
vitro
model
might
use
identif
live
attenu
respiratori
vaccin
ongo
phase
trial
current
enrol
seroposit
children
progress
seroneg
infant
children
tabl
sever
promis
candid
vaccin
evalu
clinic
trial
past
year
among
live
attenu
rsv
piv
vaccin
use
seroneg
infant
subunit
rsv
vaccin
use
highrisk
adult
vlpbase
rsv
vaccin
mani
year
compani
interest
rsv
vaccin
develop
chang
dramat
sever
addit
compani
new
platform
compet
develop
vaccin
one
tell
whether
live
attenu
subunit
vlp
replic
nonrepl
vector
vaccin
turn
success
phase
hope
new
competit
help
bring
much
need
respiratori
vaccin
market
sooner
everi
year
without
lost
year
especi
nt
receiv
care
need
tabl
ongo
recent
complet
rsv
mpv
piv
vaccin
trial
